Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Amantadine in Moderate or Severe COVID-19
NCT04952519Phase 3Terminated
- Sponsor
- Noblewell Sp. z o.o.
- Start
- Mar 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in coronavirus disease 2019 (COVID-19) comparing Amantadine with Placebo (2 arms). Primary endpoint: Time to recovery at 28 days. Started Mar 2021; status: terminated.
02
Drugs
amantadine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04952519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04952519.